mProX™ Human SLCO1B3 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-0922-KX1564	Magic™ Human SLCO1B3 in Vitro Drug screening assay	Human	Caco-2, MDCK, HEK293, CHO, membrane vesicles, and various transfected cells lines	Activity Assay (High throughput screening assays; Large scale single dose, duplicate profiling; IC50 profiling; Ki determination assay; Substrate determination assay )

Product Information

Target Protein

SLCO1B3

Target Family

SLC Transporter

Target Protein Species

Human

Host Cell Type

MCF-10A; CHO-K1; HEK293

Target Classification

Transporter Cell Lines

Target Research Area

Digestive and Renal Research; Metabolic Research

Related Diseases

Hyperbilirubinemia; Dubin-Johnson Syndrome

Gene ID

28234

UniProt ID

Q9NPD5

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The protein known as organic anion transporting polypeptide 1B3, or OATP1B3, is made by the SLCO1B3 gene. This protein is present in the cells of the liver; it carries substances from the blood into the liver where they are eliminated from the body. Bilirubin is broken down in the digestive juice known as bile in the liver and then eliminated from the body. In addition, the OATP1B3 protein carries several hormones, poisons, and medications into the liver where they are eliminated from the body. Medications for heart disease, some antibiotics, some anti-cancer treatments, and statins, which are used to treat excessive cholesterol, are among the medications carried by the OATP1B3 protein. The customized SLCO1B3 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Shirley

I have used the human SLCO1B3 cell line extensively in my studies, and it consistently delivered outstanding performance. Jul 07 2021

chat Verified Customer

chat Christopher

The performance of the SLCO1B3 overexpression cell line was consistent, and the company's support team was responsive and helpful throughout the process. Jul 21 2020

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 SLCO1B3 mRNA was highly expressed in normal breast cells MCF-10A.

The MDA-MB-453 cell line exhibited a non-uniform relative expression level of SLCO1B3 among four distinct cell lines. Of the studied cell lines, MDA-MB-231 had the highest relative expression level of SLCO1B3 mRNA, whereas BT-549 had the lowest relative expression level. For the overexpression experiment, BT-549 breast cancer cells were chosen, and MDA-MB-231 breast cancer cells were employed for the knockdown experiment.

Ref: Tang, Tiantian, et al. "Highly expressed SLCO1B3 inhibits the occurrence and development of breast cancer and can be used as a clinical indicator of prognosis." Scientific reports 11.1 (2021): 631.

Pubmed: 33436824

DOI: 10.1038/s41598-020-80152-0

Research Highlights

This review covers the mechanisms of resistance in brief and focuses on the newly discovered roles of the SLCO1B3 protein in the development of chemotherapy resistance in cancer. Clarifying SLCO1B3's role in chemoresistance could lead to the development of new therapeutic approaches for the treatment of cancer.
Sun, Ruipu, et al. "The emerging role of the SLCO1B3 protein in cancer resistance." Protein and Peptide Letters 27.1 (2020): 17-29.
Pubmed: 31556849 DOI: 10.2174/0929866526666190926154248

The SLCO1B3 controls the intracellular concentrations of cabazitaxel and docetaxel, which in turn affects the effectiveness of taxanes. In prostate cancer, loss of the drug transporter SLCO1B3 may be the cause of taxane resistance.
de Morrée, Ellen S., et al. "Loss of SLCO1B3 drives taxane resistance in prostate cancer." British journal of cancer 115.6 (2016): 674-681.
Pubmed: 27537383 DOI: 10.1038/bjc.2016.251